Peloton Therapeutics, Inc., is a clinical-stage biotechnology company that discovers and develops first-in-class, small molecule cancer therapies targeting unexploited molecular vulnerabilities.  Peloton Therapeutics’ lead program, PT2385, is a first-in-class small molecule targeting hypoxia inducible factor-2α (HIF-2α), a transcription factor implicated in the development and progression of renal and other cancers.


Click above image for video discussing Peloton’s HIF-2a inhibitor.

Peloton Therapeutics, Inc. Presents Positive Preclinical Data on First HIF-2α Inhibitor in Combination with Immuno-oncology Agents at 2016 AACR Annual Meeting


  • Lead investigational compound PT2385 has synergistic activity with immuno-oncology agents in preclinical tumor models 

AACR Annual Meeting 2016
April 19, 2016 01:00 PM Eastern Daylight Time

Link to Article

AACR 2016 Poster